Meeting
2019 ASCO Annual Meeting
Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.
Authors
Sibylle Loibl
German Breast Group (GBG) and Centre for Haematology and Oncology Bethanien, Frankfurt, Neu-Isenburg, Germany
Sibylle Loibl , Bruno Valentin Sinn , Thomas Karn , Michael Untch , Hans-Peter Sinn , Karsten Ernst Weber , Claus Hanusch , Jens Bodo Huober , Peter Staib , Ralf Lorenz , Jens Uwe Blohmer , Frederik Marmé , Wolfgang D Schmitt , Kerstin Rhiem , Marion van Mackelenbergh , Peter A. Fasching , Song Wu , Brandon W. Higgs , Andreas Schneeweiss , Carsten Denkert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT02685059
Citation
J Clin Oncol 37, 2019 (suppl; abstr 509)
DOI
10.1200/JCO.2019.37.15_suppl.509
Abstract #
509
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Genomic profiling of breast cancer brain metastases reveals targetable alterations.
First Author: Sheheryar Kairas Kabraji
Poster
2023 ASCO Genitourinary Cancers Symposium
Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
First Author: Tanya Jindal
Poster
2022 ASCO Annual Meeting
Genomic aberrations associated with overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or placebo (PBO) plus androgen deprivation therapy (ADT) in TITAN.
First Author: Neeraj Agarwal
Poster
2022 ASCO Genitourinary Cancers Symposium
Comprehensive molecular characterization of muscle-invasive bladder cancer (MIBC) treated with durvalumab plus olaparib in the neoadjuvant setting: Neodurvarib trial.
First Author: Juan Francisco Rodriguez-Moreno